Claims for Patent: 7,410,957

Summary for Patent: 7,410,957

Title:	Method of treatment using bisphosphonic acid
Abstract:	The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Inventor(s):	Bauss; Frieder (Neuhofen, DE), Pichler; Bernhard (Ketsch, DE), Turley; Stephen (Bottmingen, CH)
Assignee:	Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:	10/430,007
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,410,957
Patent Claims:	1. A method for treating osteoporosis comprising commencing treatment by orally administering to a subject in need of such treatment, on a single day, a first dose in the form of a tablet, wherein said tablet comprises an amount of a pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid and continuing said treatment by orally administering, once monthly on a single day, a tablet comprising an amount of a pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid. 2. The method of claim 1, wherein the pharmaceutically acceptable salt is a sodium salt of ibandronic acid. 3. The method of claim 2 wherein the pharmaceutically acceptable salt is a monosodium, disodium, or trisodium salt of ibandronic acid. 4. The method of claim 3 wherein the pharmaceutically acceptable salt is a monosodium salt of ibandronic acid. 5. The method of claim 4 wherein the pharmaceutically acceptable monosodium salt of ibandronic acid is a monohydrate. 6. A method for treating osteoporosis consisting of orally administering to a subject in need of such treatment, once monthly on a single day, a tablet comprising an amount of a pharmaceutically acceptable salt of ibandronic acid that is equivalent to about 150 mg of ibandronic acid. 7. The method of claim 6, wherein the pharmaceutically acceptable salt is a sodium salt of ibandronic acid. 8. The method of claim 7 wherein the pharmaceutically acceptable salt is a monosodium, disodium, or trisodium salt of ibandronic acid. 9. The method of claim 8 wherein the pharmaceutically acceptable salt is a monosodium salt of ibandronic acid. 10. The method of claim 9 wherein the pharmaceutically acceptable monosodium salt of ibandronic acid is a monohydrate. 11. The method of claim 2 wherein the tablet comprises at least one member selected from the group consisting of lactose, maize starch, talc, stearic acid, a salt of stearic acid, polyvinylpyrrolidone, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, silicon dioxide, hydroxypropyl methyl cellulose, titanium dioxide, and polyethylene glycol 6000. 12. The method of claim 2 wherein the tablet comprises stearic acid. 13. The method of claim 2 wherein the tablet comprises a salt of stearic acid. 14. The method of claim 2 wherein the tablet comprises silicon dioxide. 15. The method of claim 2 wherein the tablet comprises cross-linked polyvinylpyrrolidone. 16. The method of claim 7 wherein the tablet comprises at least one member selected from the group consisting of lactose, maize starch, talc, stearic acid, a salt of stearic acid, polyvinylpyrrolidone, microcrystalline cellulose, cross-linked polyvinylpyrrolidone, silicon dioxide, hydroxypropyl methyl cellulose, titanium dioxide, and polyethylene glycol 6000. 17. The method of claim 7 wherein the tablet comprises stearic acid. 18. The method of claim 7 wherein the tablet comprises a salt of stearic acid. 19. The method of claim 7 wherein the tablet comprises silicon dioxide. 20. The method of claim 7 wherein the tablet comprises cross-linked polyvinylpyrrolidone.